Physician profile
Christopher G Fleissner
NPI 1588827828
$1,073.36
in general payments reported to CMS, 2019-2025
11 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $112 · 2024: $39.97 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.40 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $205.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.29 | 2019 | |
| Lilly USA, LLC | $102.89 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $79.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $79.28 | 2019 | |
| Horizon Therapeutics Plc | $47.42 | 2019-2020 | |
| Organon LLC | $26.57 | 2025 | Nexplanon |
| Pfizer INC. | $18.39 | 2025 | |
| Biodelivery Sciences International, INC. | $13.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fleissner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.